Current Report Filing (8-k)
March 13 2023 - 8:01AM
Edgar (US Regulatory)
0001349929
false
0001349929
2023-03-07
2023-03-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): March 7, 2023
VYANT
BIO, INC.
(Exact
Name of Company as Specified in its Charter)
Delaware |
|
001-35817 |
|
04-3462475 |
(State
or Other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
2
Executive Campus
2370
State Route 70, Suite 310
Cherry
Hill, NJ 08002
(Address
of Principal Executive Offices) (Zip Code)
Company’s
telephone number, including area code (201) 479-1357
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any
of the following provisions (see General Instruction A.2. below):
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common Stock |
|
VYNT |
|
The Nasdaq Capital Market |
Indicate
by check mark whether the Company is an emerging growth company as defined by Rule 405 of the Securities Act of 1933 (17 §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the Company has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01 Other Events.
San
Diego Facility Closure
On
March 9, 2023, the Company’s subsidiary, StemoniX, Inc., terminated its January 2022, lease agreement (the “San Diego Lease”)
with Nancy Ridge Technology Center, L.P. for the lease of approximately 5,000 rentable square feet of laboratory and office space for
an original term of approximately 5 years. The San Diego Lease was guaranteed by the Company. The effective date of the termination is
March 31, 2023. The landlord is retaining approximately two months rent ($45,000) as an early termination fee.
On
March 7, 2023, the Company sold its equipment in its San Diego laboratory to a third party and received $200,000 in consideration for
such sale.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
VYANT BIO,
INC. |
|
|
|
|
Date: |
March 13, 2023 |
By: |
/s/
Andrew D. C. LaFrence |
|
|
Name: |
Andrew D. C. LaFrence |
|
|
Title: |
President,
Chief Executive Officer, and Chief Financial
Officer |
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Apr 2024 to May 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From May 2023 to May 2024